title: [Evaluation of cefpodoxime proxetil in the pediatric field].
abstract: Pharmacokinetic and clinical evaluation of cefpodoxime proxetil (CPDX-PR, CS-807) were performed in the field of pediatrics. The obtained results are summarized as follows. 1. Peak serum concentrations of CPDX upon single oral doses of 3.0 mg/kg and 4.4 mg/kg of CPDX-PR were 1.26-1.46 micrograms/ml and 1.45 micrograms/ml, respectively, achieved at 4 hours and 1 hour after administration. Urinary excretion rates for CPDX in the first 8 hours ranged between 28.1 and 30.2%. 2. Clinical efficacy rates for pediatric infections obtained at single dose levels ranging 3 to 6 mg/kg were 97.5%, and that at a single dose of 1 mg/kg were 90.9%. 3. Bacteriological effectiveness was determined in 45 strains identified in recent cases. Eradication rates for these bacteria at dose levels of 3 to 6 mg/kg and 1 mg/kg were 91.3% and 95.5%, respectively. 4. No side effect nor abnormal laboratory test data were found in any of the cases examined. From these results, CPDX-PR appeared to be a useful antibiotic agent in the field of pediatrics.
authors: Department of Pediatrics, Oquchi Higashi General Hospital.
authors: K
authors: K
authors: Niino
authors: H
authors: H
authors: Sato
authors: A
authors: A
authors: Narita
authors: S
authors: S
authors: Nakazawa
authors: H
authors: H
authors: Suzuki
authors: K
authors: K
authors: Matsumoto
authors: S
authors: S
authors: Nakazawa
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D001991:Bronchitis / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D015296:Ceftizoxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D012541:Scarlet Fever / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D014069:Tonsillitis / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D000097623:Cefpodoxime; D000097627:Cefpodoxime Proxetil
chemical_list: D015296:Ceftizoxime; D000097623:Cefpodoxime; D000097627:Cefpodoxime Proxetil